E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/30/2006 in the Prospect News Biotech Daily.

Jefferies rates Albany at underperform

Albany Molecular Research, Inc. was given an underperform rating by Jefferies & Co., Inc. analyst David Windley. A recent court ruling that denied sanofi-aventis/Albany's request for a preliminary injunction allows the continuing generic erosion of Allegra sales and decline of Albany's royalty stream, which represents its primary profit stream. Jefferies said it expects the stock to decline further. Shares of the Albany, N.Y., pharmaceutical company were down 23 cents, or 1.99%, at $11.31 on volume of 153,984 shares versus the three-month running average of 155,525 shares. (Nasdaq: AMRI)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.